Cancer Drug Parity Act Reintroduced to Eliminate Out-of-Pocket Cost Disparities Between Oral and IV Cancer Therapies
核心洞察
Senators Tina Smith and Jerry Moran reintroduced the bipartisan Cancer Drug Parity Act to ensure patients do not face higher out-of-pocket costs for oral anticancer therapies compared to intravenous treatments.
A Susan G. Komen (搜索) study found that patients receiving IV treatment were more than three times as likely to report significant productivity impact compared to those on oral therapies, with 54% frequently taking paid time off versus just 5%.
The Coalition to Improve Access to Cancer Care (CIACC), convened by the International Myeloma Foundation (搜索), is leading advocacy efforts alongside organizations including the Lymphoma Research Foundation (搜索).
WASHINGTON, July 21, 2026 — The Coalition to Improve Access to Cancer Care (CIACC), convened by the International Myeloma Foundation (搜索) (IMF), applauded Senators Tina Smith (D-MN) and Jerry Moran (R-KS) for reintroducing the bipartisan Cancer Drug Parity Act. The legislation seeks to ensure that patients do not face higher out-of-pocket costs simply because their prescribed anticancer treatment is taken orally rather than administered intravenously.
As advances in cancer research continue to transform treatment, oral anticancer therapies have become the standard of care for many cancers. Yet outdated insurance benefit designs continue to leave many patients paying significantly more out of pocket for oral medications than for physician-administered therapies, creating financial barriers that can limit access to the treatment their healthcare provider recommends.
Impact of Treatment Administration on Patients' Daily Lives
The need for modernized insurance coverage is reinforced by a recent Susan G. Komen (搜索) study examining the impact of treatment administration on patients' daily lives. According to the study, people receiving intravenous treatment were more than three times as likely as those receiving oral therapy to report that treatment had a significant impact on their productivity at work or school. The study also found that 54% of people receiving IV treatment frequently took paid time off from work and 33% frequently took unpaid leave, compared with just 5% and 9%, respectively, among those receiving oral therapies.
These findings underscore the broader societal and economic implications of treatment administration route, beyond the direct medical considerations. Oral therapies offer patients greater flexibility and reduced disruption to their professional and personal lives, yet the current insurance framework often penalizes patients for choosing these more convenient and less disruptive treatment options.
Advocacy and Coalition Support
"The way a cancer treatment is administered should never determine whether a patient can afford it," said Danielle Doheny, Director of Public Policy and Advocacy at the International Myeloma Foundation (搜索). "Oral therapies have become an essential part of modern cancer care, yet insurance coverage has not kept pace with these advances. The Cancer Drug Parity Act will help ensure treatment decisions are based on clinical need rather than financial barriers. We thank Senators Smith and Moran for their continued bipartisan leadership and urge Congress to advance this important legislation."
Convened by the International Myeloma Foundation (搜索), CIACC brings together patient advocacy organizations, provider organizations, professional societies, and other stakeholders committed to ensuring equitable access to cancer care. Coalition members from across the oncology community expressed strong support for the legislation.
"The advent of effective oral therapies marked a significant change in the way many people with lymphoma (搜索) and CLL (搜索) are treated," said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation (搜索). "To ensure patients receive the most effective therapy at the right time, and achieve the best outcome, we must ensure access to these treatments. The Cancer Drug Parity Act is an important step to achieve this."
The reintroduction of the Cancer Drug Parity Act represents a continued bipartisan effort to align insurance coverage with the realities of modern oncology practice, where oral therapies play an increasingly central role in treatment paradigms across multiple cancer types.